德拉维特综合征:在分子诊断-治疗框架内对SCN1A介导的性神经发育障碍的新见解
Guirui Zhang1,2, Shupeng Huang1, Mingzhen Wei1
1Department of Medical Oncology, Liuzhou Workers' Hospital, Liuzhou, China.
Frontiers in neuroscience
|August 7, 2025
概括
德拉维特综合征 (DS) 是一种严重的,由SCN1A基因突变引起. 新的诊断和基因向疗法旨在恢复大脑功能并改善患者的治疗结果.
科学领域:
- 遗传学和神经学 遗传学和神经学
- 的分子病变发生因子
- 神经发育障碍 神经发育障碍
背景情况:
- 德拉维特综合征 (DS) 是一种罕见的,严重的遗传脑病.
- 具有耐药性和神经发育回归的特征.
- 主要是由新的SCN1A基因突变 (~80%的病例) 引起的.
研究的目的:
- 综合当前关于DS分子病原学的知识.
- 审查精确诊断方面的进展.
- 探索创新的,针对机制的治疗策略.
主要方法:
- 分析SCN1A基因突变及其对Nav1.1通道的影响.
- 整合遗传,电生理学和神经成像数据用于诊断.
- 评估临床前和新兴的治疗方法.
主要成果:
- SCN1A突变会损害GABAergic内部神经元中的Nav1.1功能,破坏大脑激发抑制平衡.
- 多基因相互作用和细胞缺陷加剧过度兴奋性.
- 先进的诊断加速了准确的诊断,减少了误诊.
结论:
- 针对DS的SCN1A中心精密医学正在出现.
- 治疗策略正在从症状控制转向机制驱动的干预.
- 诊断和治疗的跨学科整合对于未来的进步至关重要.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
450
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
450
Epilepsy and Seizures: Overview
280
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
280
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
961
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
961
Seizures: Classification
593
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
593
Antiepileptic Drugs: GABAergic Pathway Potentiators
650
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
650


